Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
SAN DIEGO, May 02, 2017 -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, will release its first quarter 2017 financial results after the market closes on Tuesday, May 9, 2017. The press release will be followed by a conference call on Wednesday, May 10, 2017 at 4:30 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review financial results and discuss other business matters.
The conference call dial-in numbers are (855) 765-5682 for domestic callers and (919) 825-3204 for international callers. The conference ID number for the call is 14568675. Participants may access the live webcast via a link on the Vital Therapies website in the Investors Relations section under Events at: http://ir.vitaltherapies.com/. The webcast will be archived on the Company's website shortly after completion of the call.
For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 7:30 p.m. ET on May 10, 2017 to 7:30 p.m. ET on May 17, 2017. The conference call replay numbers for domestic and international callers are (855) 859-2056 and (404) 537-3406, respectively. The conference ID number for the replay is 14568675.
About Vital Therapies, Inc.
Vital Therapies, Inc. is a biotherapeutic company developing a cell-based therapy targeting the treatment of acute forms of liver failure. The Company's ELAD System is an extracorporeal human allogeneic cellular liver therapy currently in phase 3 clinical trials. Vital Therapies, Inc. is based in San Diego, California. Vital Therapies® and ELAD® are trademarks of Vital Therapies, Inc.
Contact: Vital Therapies, Inc. Al Kildani Vice President, Investor Relations and Business Development 858-673-6840 [email protected]
